Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + L-DOS47 + Pemetrexed Disodium|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|L-DOS47||L-DOS47 comprises urease linked to a monoclonal antibody that targets CEACAM6, resulting localization to tumor sites by the CEACAM6 antibody and conversion of urea to ammonia by the urease enzyme with concomitant pH increase, which potentially leads to cytoxicity in tumor cells (J Thorac Oncol, Vol 12 , Issue 1 , S1071-S1072, PMID: 28871252).|
|Pemetrexed Disodium||Alimta||LY231514||Chemotherapy - Antimetabolite 11||Alimta (Pemetrexed Disodium) is an antifolate, which inhibits thymidylate synthase (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02309892||Phase I||Carboplatin + L-DOS47 + Pemetrexed Disodium||A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC||Completed|